Funding round
Kallyope Series B
Kallyope, which works in neurological disease therapeutics discovery in New York, raised $66M in a Series B round announced on 22 Feb 2018, led by Lux Capital. 7 firms took part. It is Kallyope's second venture round on record; the one before was a Series A in Dec 2015.
$66M
Amount raised
Not disclosed
Post-money valuation
7
Investors
1 lead
Valuation
What this round says about the price
Kallyope did not disclose a valuation in this round. It came 26 months after Kallyope's Series A. It is 14% of the $458M Kallyope has raised in the venture rounds on record. Kallyope raised again 25 months later: a Series C round of $112M in Mar 2020. Its next priced round, a Series D in Feb 2022, valued it at $1.30B.
Investors
Who put money in
Lux Capital led the round with 6 other firms.
Lead investor
- Lux Capital backs 194 venture-backed companies new investor
Also in the round
- backs 24 venture-backed companies new investor
- backs 98 venture-backed companies new investor
- backs 38 venture-backed companies new investor
- Alexandria Venture Investments new investor
- Euclidean Capital new investor
- Two Sigma Ventures backs 60 venture-backed companies new investor
Use of proceeds
What the money is for
According to the announcement, the money goes to hiring, product development, scaling operations and working capital.
- Hiring
- Product development
- Scaling operations
- Working capital
Comparable rounds
How it compares
24 Series B rounds in Biotechnology within a year either side disclosed an amount; the median was $25M, and this round was 2.6 times the median. The closest in time, other companies' Series B rounds in Biotechnology:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Biotechnology | 16 Jan 2018 | $11M | not disclosed | KTB Network and DCI Partners |
| Biotechnology | 27 Nov 2017 | $57M | not disclosed | RA Capital |
| Biotechnology | 16 May 2018 | $38M | not disclosed | HSG and LYFE Capital |
| Biotechnology | 23 May 2018 | $26M | $79M | Pfizer Ventures and Merck Global Health Innovation Fund |
| Biotechnology | 17 Nov 2017 | $12M | not disclosed | Épimède |
| Biotechnology | 28 Nov 2017 | $10M | not disclosed | not named |
| Biotechnology | 16 Jul 2018 | $19M | not disclosed | Global Health Investment Corporation |
| Biotechnology | 9 Jul 2018 | $15M | not disclosed | not named |
Sources
Where this comes from
Reported by 4 sources.
Questions
Frequently asked
How much did Kallyope raise in its Series B round?
Kallyope raised $66M in its Series B round, announced in Feb 2018.
Who led Kallyope's Series B round?
Lux Capital led it, with The Column Group, Polaris Partners, Illumina Ventures, Alexandria Venture Investments and Euclidean Capital and 1 more.
What was Kallyope's valuation at the Series B round?
It was not disclosed.
How does it compare with other Series B rounds in Biotechnology?
24 Series B rounds in Biotechnology within a year either side disclosed an amount; the median was $25M, and this round was 2.6 times the median.
Did Kallyope raise again after this round?
Yes: a Series C round in Mar 2020 of $112M.